Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ACRS |
---|---|---|
09:32 ET | 33983 | 4.22 |
09:33 ET | 9368 | 4.25 |
09:35 ET | 3694 | 4.21 |
09:37 ET | 8925 | 4.2 |
09:39 ET | 10050 | 4.12 |
09:42 ET | 9021 | 4.1459 |
09:44 ET | 12137 | 4.24 |
09:46 ET | 17065 | 4.28 |
09:48 ET | 23253 | 4.3 |
09:50 ET | 44156 | 4.3 |
09:51 ET | 10105 | 4.28 |
09:53 ET | 1300 | 4.29 |
09:55 ET | 31439 | 4.275 |
09:57 ET | 2700 | 4.3247 |
10:00 ET | 1900 | 4.325 |
10:02 ET | 12284 | 4.27 |
10:04 ET | 4200 | 4.25 |
10:06 ET | 2523 | 4.28 |
10:08 ET | 57786 | 4.34 |
10:09 ET | 14882 | 4.34 |
10:11 ET | 4695 | 4.34 |
10:13 ET | 2787 | 4.31 |
10:15 ET | 5963 | 4.3152 |
10:18 ET | 2150 | 4.3259 |
10:20 ET | 2002 | 4.32 |
10:22 ET | 9763 | 4.34 |
10:24 ET | 6760 | 4.34 |
10:26 ET | 30376 | 4.42 |
10:27 ET | 9685 | 4.33 |
10:29 ET | 4418 | 4.32 |
10:31 ET | 4222 | 4.32 |
10:33 ET | 2859 | 4.34 |
10:36 ET | 3539 | 4.33 |
10:38 ET | 1400 | 4.32 |
10:40 ET | 1436 | 4.33 |
10:42 ET | 7206 | 4.31 |
10:44 ET | 1836 | 4.3193 |
10:45 ET | 9403 | 4.27 |
10:47 ET | 1600 | 4.29 |
10:49 ET | 2544 | 4.3 |
10:51 ET | 2124 | 4.2901 |
10:54 ET | 4243 | 4.25 |
10:56 ET | 2900 | 4.26 |
10:58 ET | 4733 | 4.28 |
11:00 ET | 2843 | 4.3 |
11:02 ET | 4885 | 4.27 |
11:03 ET | 15180 | 4.26 |
11:05 ET | 800 | 4.27 |
11:07 ET | 1870 | 4.26 |
11:09 ET | 10603 | 4.22 |
11:12 ET | 14041 | 4.19 |
11:14 ET | 10876 | 4.195 |
11:16 ET | 5674 | 4.22 |
11:18 ET | 1000 | 4.25 |
11:20 ET | 48421 | 4.19 |
11:21 ET | 3700 | 4.19 |
11:23 ET | 7626 | 4.17 |
11:25 ET | 5793 | 4.175 |
11:27 ET | 9131 | 4.1886 |
11:30 ET | 4638 | 4.192 |
11:32 ET | 31190 | 4.1175 |
11:34 ET | 32430 | 4.09 |
11:36 ET | 4520 | 4.09 |
11:38 ET | 8952 | 4.09 |
11:39 ET | 7522 | 4.1 |
11:41 ET | 12798 | 4.07 |
11:43 ET | 21220 | 4.08 |
11:45 ET | 15791 | 4.09 |
11:48 ET | 3879 | 4.09 |
11:50 ET | 2820 | 4.09 |
11:52 ET | 6723 | 4.06 |
11:54 ET | 5305 | 4.055 |
11:56 ET | 14774 | 4.06 |
11:57 ET | 5856 | 4.07 |
11:59 ET | 5400 | 4.0796 |
12:01 ET | 8277 | 4.072 |
12:03 ET | 9580 | 4.03 |
12:06 ET | 11722 | 4.03 |
12:08 ET | 3400 | 4.0483 |
12:10 ET | 6507 | 4.01 |
12:12 ET | 58109 | 3.93 |
12:14 ET | 21685 | 3.95 |
12:15 ET | 23266 | 3.9612 |
12:17 ET | 3475 | 3.97 |
12:19 ET | 14776 | 3.9801 |
12:21 ET | 15930 | 4.005 |
12:24 ET | 8419 | 4.04 |
12:26 ET | 6586 | 4.03 |
12:28 ET | 9710 | 3.96 |
12:30 ET | 9697 | 3.9467 |
12:32 ET | 7142 | 3.9491 |
12:33 ET | 5865 | 3.93 |
12:35 ET | 455902 | 3.99 |
12:37 ET | 14150 | 4 |
12:39 ET | 592 | 3.985 |
12:42 ET | 4495 | 3.99 |
12:44 ET | 6851 | 3.98 |
12:46 ET | 2800 | 3.97 |
12:48 ET | 7514 | 3.99 |
12:50 ET | 300 | 4 |
12:51 ET | 4754 | 4.03 |
12:53 ET | 4000 | 4.0464 |
12:55 ET | 4079 | 4.0403 |
12:57 ET | 1826 | 4.0607 |
01:00 ET | 2197 | 4.0693 |
01:02 ET | 5083 | 4.0611 |
01:04 ET | 700 | 4.0985 |
01:06 ET | 3765 | 4.11 |
01:08 ET | 3044 | 4.12 |
01:09 ET | 1400 | 4.12 |
01:11 ET | 2645 | 4.09 |
01:13 ET | 1807 | 4.1015 |
01:15 ET | 14599 | 4.11 |
01:18 ET | 2701 | 4.13 |
01:20 ET | 2968 | 4.125 |
01:22 ET | 3056 | 4.135 |
01:24 ET | 2285 | 4.1609 |
01:26 ET | 2324 | 4.165 |
01:27 ET | 900 | 4.1525 |
01:29 ET | 4556 | 4.14 |
01:31 ET | 2942 | 4.14 |
01:33 ET | 15428 | 4.1301 |
01:36 ET | 6539 | 4.11 |
01:38 ET | 3304 | 4.13 |
01:40 ET | 1352 | 4.135 |
01:42 ET | 800 | 4.17 |
01:44 ET | 2250 | 4.17 |
01:45 ET | 1156 | 4.16 |
01:47 ET | 700 | 4.165 |
01:49 ET | 5737 | 4.16 |
01:51 ET | 1427 | 4.155 |
01:54 ET | 1228 | 4.145 |
01:56 ET | 1207 | 4.15 |
01:58 ET | 3168 | 4.13 |
02:00 ET | 1200 | 4.125 |
02:02 ET | 30869 | 4.17 |
02:03 ET | 8571 | 4.15 |
02:05 ET | 693 | 4.14 |
02:07 ET | 455 | 4.1301 |
02:09 ET | 4159 | 4.14 |
02:14 ET | 659 | 4.14 |
02:16 ET | 1172 | 4.147 |
02:18 ET | 2100 | 4.13 |
02:20 ET | 1300 | 4.13 |
02:21 ET | 5210 | 4.09 |
02:23 ET | 3942 | 4.09 |
02:25 ET | 6822 | 4.08 |
02:27 ET | 2387 | 4.12 |
02:30 ET | 1303 | 4.155 |
02:32 ET | 3106 | 4.155 |
02:34 ET | 510 | 4.155 |
02:36 ET | 8104 | 4.17 |
02:38 ET | 13622 | 4.17 |
02:39 ET | 100 | 4.17 |
02:41 ET | 5722 | 4.155 |
02:43 ET | 5200 | 4.13 |
02:48 ET | 6590 | 4.1249 |
02:50 ET | 14996 | 4.07 |
02:52 ET | 11009 | 4.03 |
02:54 ET | 13236 | 4.02 |
02:56 ET | 16739 | 4.0099 |
02:57 ET | 7247 | 3.99 |
02:59 ET | 13477 | 3.9998 |
03:01 ET | 12826 | 4 |
03:03 ET | 1646 | 3.9992 |
03:06 ET | 4550 | 3.9818 |
03:08 ET | 5628 | 4.01 |
03:10 ET | 6925 | 4 |
03:12 ET | 1744 | 4.01 |
03:14 ET | 2429 | 4 |
03:15 ET | 5849 | 3.98 |
03:17 ET | 1000 | 3.99 |
03:19 ET | 5316 | 3.96 |
03:21 ET | 35876 | 3.9281 |
03:24 ET | 18392 | 3.9 |
03:26 ET | 26076 | 4.005 |
03:28 ET | 1200 | 3.995 |
03:30 ET | 9510 | 3.97 |
03:32 ET | 410 | 4 |
03:33 ET | 25845 | 4.03 |
03:35 ET | 6750 | 4.03 |
03:37 ET | 20760 | 4.02 |
03:39 ET | 4892 | 4.02 |
03:42 ET | 4491 | 4.01 |
03:44 ET | 16537 | 3.98 |
03:46 ET | 8446 | 3.95 |
03:48 ET | 29045 | 3.915 |
03:50 ET | 21108 | 3.915 |
03:51 ET | 24051 | 3.85 |
03:53 ET | 27015 | 3.875 |
03:55 ET | 8842 | 3.855 |
03:57 ET | 35574 | 3.875 |
04:00 ET | 523388 | 3.8 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Aclaris Therapeutics Inc | 308.6M | -7.3x | --- |
Artiva Biotherapeutics Inc | 264.1M | 0.0x | --- |
C4 Therapeutics Inc | 283.1M | -2.5x | --- |
Mersana Therapeutics Inc | 242.9M | -3.3x | --- |
Uniqure NV | 284.9M | -1.2x | --- |
Tango Therapeutics Inc | 389.9M | -3.4x | --- |
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The Company's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The Company's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $308.6M |
---|---|
Revenue (TTM) | $27.1M |
Shares Outstanding | 71.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.39 |
EPS | $-0.52 |
Book Value | $2.22 |
P/E Ratio | -7.3x |
Price/Sales (TTM) | 11.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -170.99% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.